Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Change in Account Payables (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Change in Account Payables for 11 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables changed N/A to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a N/A change, with the full-year FY2025 number at $2.1 million, up 486.22% from a year prior.
  • Change in Account Payables was $1.0 million for Q4 2025 at Crescent Biopharma, up from -$318419.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.6 million in Q3 2024 to a low of -$1.0 million in Q2 2022.
  • A 5-year average of $41679.0 and a median of $50861.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 390.72% in 2023, then surged 1667.01% in 2024.
  • Crescent Biopharma's Change in Account Payables stood at $717184.0 in 2021, then crashed by 83.54% to $118066.0 in 2022, then surged by 355.87% to $538230.0 in 2023, then surged by 190.21% to $1.6 million in 2024, then plummeted by 34.44% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Change in Account Payables are $1.0 million (Q4 2025), -$318419.0 (Q2 2025), and -$224633.0 (Q1 2025).